HDAC-IN-79

HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM; ), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition[1].

Product Specifications

UNSPSC

12352211

Target

Apoptosis; Autophagy; HDAC; Xanthine Oxidase

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/hdac-in-79.html

Smiles

CC(C)COC1=CC=C(C2=NC(C)=C(C(NCCCCCCC(NO)=O)=O)S2)C=C1C#N

Molecular Formula

C23H30N4O4S

Molecular Weight

458.57

References & Citations

[1]Liao Z Y, et al. Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activity[J]. European journal of medicinal chemistry, 279: 116866.